Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT06097299

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Conditions: Respiratory Syncytial Virus

Sex: All
Ages: 2 Years – 17 Years
Healthy volunteers: Yes
Phase: PHASE2
Enrollment: 349
Sponsor: ModernaTX, Inc.

Location: Velocity Clinical Research, Phoenix Phoenix Arizona

Summary

Part A: The purpose is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to \

Eligibility Criteria

Key Inclusion Criteria: Part A Cohort 1: * 2 to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06097299). StuddyBuddy aggregates publicly available trial information.